Jefferies analyst Thomas Wei reiterated a Buy rating and $21 price target on Immunogen Inc. (NASDAQ: IMGN) Monday, noting positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE